Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Todd L. Rosenblat, MD, Michael R. McDevitt, PhD, Neeta Pandit-Taskar, MD, Jorge A. Carrasquillo, MD, Suzanne M. Chanel, RN, Kevin Zikaras, BS, Mark G. Frattini, MD, PhD, Peter G. Maslak, M.D., Dragan Cicic, MD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD

Blood (2011) 118 (21): 768.

https://doi.org/10.1182/blood.V118.21.768.768

Published: 2011

Journal Articles

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)

Todd Rosenblat, MD, MS, Michael R. McDevitt, PhD, Deborah A. Mulford, MD, Neeta Pandit-Taskar, MD, Mark A. Weiss, MD, Mark L. Heaney, MD, PhD, Suzanne Chanel, RN, Alfred Morgenstern, PhD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD, Joseph G. Jurcic, MD

Blood (2008) 112 (11): 2983.

https://doi.org/10.1182/blood.V112.11.2983.2983

Published: 2008

Journal Articles

The Novel Human Ph + Acute Lymphoblastic Leukemia Cell Line PhALL3.1 Is Amenable to Retroviral Gene Transfer and Mimics Human Disease Progression in SCID-Beige Mice

Mark G. Frattini, MD, PhD, Elmer Santos, MD, PhD, Mark Lawrence Heaney, MD, PhD, Peter Maslak, MD, Suresh C Jhanwar, PhD, Steven M Larson, MD, Elisa De Stanchina, PhD, Bayard Clarkson, MD, Renier J. Brentjens, MD, PhD

Blood (2008) 112 (11): 4875.

https://doi.org/10.1182/blood.V112.11.4875.4875

Published: 2008

Journal Articles

Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma

John P. Leonard, MD, Ann LaCasce, MD, Mitchell R Smith, MD, PhD, Ariela Noy, MD, Jeffrey T Yap, PhD, Annick D Van den Abbeele, MD, Jian Q Yu, MD, FRCPC, Selina Chen-Kiang, PhD, Scott A Ely, MD, PhD, Shankar Vallabhajosula, PhD, Lucian R Chirieac, MD, Steven M Larson, MD, Geoffrey I Shapiro, MD, PhD, Heiko Schoder

Blood (2008) 112 (11): 264.

https://doi.org/10.1182/blood.V112.11.264.264

Published: 2008

Journal Articles

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).

Todd L. Rosenblat, MD, Michael R. McDevitt, PhD, Neeta Pandit-Taskar, MD, Jorge A. Carrasquillo, MD, Suzanne Chanel, RN, Mark G. Frattini, MD, PhD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD, Joseph G. Jurcic, MD

Blood (2007) 110 (11): 910.

https://doi.org/10.1182/blood.V110.11.910.910

Published: 2007

NARROW

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)

The Novel Human Ph + Acute Lymphoblastic Leukemia Cell Line PhALL3.1 Is Amenable to Retroviral Gene Transfer and Mimics Human Disease Progression in SCID-Beige Mice

Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 ( 213 Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)

The Novel Human Ph + Acute Lymphoblastic Leukemia Cell Line PhALL3.1 Is Amenable to Retroviral Gene Transfer and Mimics Human Disease Progression in SCID-Beige Mice

Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only